Two days after the FDA revealed that it had halted enrollment in trials of respiratory syncytial virus (RSV) vaccines that ...

Following news of RSV lower respiratory tract infections in infants immunized with Moderna’s investigational RNA vaccines, ...

Shares of Moderna Inc. MRNA slipped 2.31% to $41.83 Friday, on what proved to be an all-around mixed trading session for the ...

MicroStrategy Inc, the dot-com-era software maker whose metamorphosis into a leveraged bet on bitcoin has transfixed Wall ...

Moderna stock remains under pressure with analysts projecting steep losses in the fourth quarter. Is MRNA stock a sell in ...

If you want to stay updated on the latest options trades for Moderna, Benzinga Pro gives you real-time options trades alerts.

Shares of Moderna Inc. MRNA sank 0.09% to $42.82 Thursday, on what proved to be an all-around dismal trading session for the ...

Palantir and bitcoin play MicroStrategy are expected to get a Nasdaq 100 index invite Friday. Will Moderna and Super Micro ...

In the chaotic early days of the pandemic, Wall Street scrambled to place bets on the companies that looked the most likely to thrive the uncharted waters that were rising all around us. The early ...

Norovirus vaccines face significant hurdles, with virtually no success from past efforts from HilleVax and Vaxxart. But ...

After several severe RSV cases were reported in a pediatric trial of Moderna's vaccine, the FDA has partially paused testing ...

Moderna (MRNA) shares tumble after Bank of America analysts reinstated its Underperform rating for the stock. In a broader note about the pharmaceutical and biotech spaces, Bank of America's team it's ...